EFG Asset Management North America Corp. Decreases Stake in Natera, Inc. $NTRA

EFG Asset Management North America Corp. reduced its stake in Natera, Inc. (NASDAQ:NTRA) by 4.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 34,021 shares of the medical research company’s stock after selling 1,467 shares during the quarter. EFG Asset Management North America Corp.’s holdings in Natera were worth $5,746,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Guided Capital Wealth Management LLC raised its holdings in shares of Natera by 0.5% in the second quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock worth $2,219,000 after buying an additional 66 shares during the last quarter. Wedmont Private Capital raised its holdings in shares of Natera by 4.9% in the second quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company’s stock worth $256,000 after buying an additional 74 shares during the last quarter. Compound Planning Inc. raised its holdings in shares of Natera by 4.2% in the first quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company’s stock worth $271,000 after buying an additional 78 shares during the last quarter. Earned Wealth Advisors LLC raised its holdings in shares of Natera by 5.0% in the first quarter. Earned Wealth Advisors LLC now owns 1,737 shares of the medical research company’s stock worth $246,000 after buying an additional 82 shares during the last quarter. Finally, Bridges Investment Management Inc. raised its holdings in shares of Natera by 5.5% in the first quarter. Bridges Investment Management Inc. now owns 1,676 shares of the medical research company’s stock worth $237,000 after buying an additional 87 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Wednesday, October 8th. BNP Paribas Exane raised shares of Natera from an “underperform” rating to a “neutral” rating and set a $172.00 price target for the company in a report on Monday, October 27th. Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a research note on Monday, October 20th. Piper Sandler reiterated an “overweight” rating and issued a $220.00 price objective (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. Finally, Cowen reiterated a “buy” rating on shares of Natera in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $194.89.

Natera Stock Performance

NTRA stock opened at $196.45 on Wednesday. The firm has a market cap of $26.96 billion, a PE ratio of -102.85 and a beta of 1.75. The firm’s fifty day moving average is $175.77 and its 200 day moving average is $162.77. Natera, Inc. has a one year low of $122.08 and a one year high of $203.23.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The firm had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm’s quarterly revenue was up 32.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. Research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Michael Burkes Brophy sold 1,867 shares of the business’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $190.64, for a total transaction of $355,924.88. Following the completion of the sale, the chief financial officer owned 64,126 shares of the company’s stock, valued at $12,224,980.64. The trade was a 2.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $198.60, for a total transaction of $595,800.00. Following the sale, the insider directly owned 112,061 shares of the company’s stock, valued at $22,255,314.60. This represents a 2.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 224,889 shares of company stock worth $43,232,062 in the last ninety days. Corporate insiders own 5.63% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.